Lymphoma

AI and robotics
#Artificial intelligence (AI) #Computational chemistry #Deep Origin #Lymphoma #Oncology

AI validates molecular glue compound that kills lymphoma cells

Deep Origin’s docking and molecular dynamics (MD) simulations have successfully rationalised researchers’ work identifying a potent compound to switch on cell-death programmes in diffuse large B cell lymphoma (DLBCL).  The study was led by researchers at Stanford University and the University of Texas MD Anderson Cancer Center. … Read More

#Cancer Research #News

CAR-T cells attacking a cancer cell
#Advanced Therapies #CAR-T #Cell therapy #Lyell Immunopharma #Lymphoma #Oncology #Phase III trial

CAR-Ts go head-to-head in first-of-its-kind clinical trial

Lyell Immunopharma has begun its PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtageneciloleucel (axi-cel).  The CAR-T therapies will be assessed in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line… Read More

#Cancer Research #News #Trending News

#FDA #Investigational New Drug (IND) #Leukaemia #Lymphoma

FDA grants IND clearance to novel BTK degrader 

A novel treatment for relapsed/refractory B-cell malignancies has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA).  APG-3288, developed by biopharmaceutical company Ascentage Pharma, is a novel next-generation BTK-targeted protein degrader. The candidate is designed to induce rapid, potent, highly selective, and sustained degradation of both wild-type BTK… Read More

#News #Regulatory

Diffuse large B-cell lymphoma
#Advanced Therapies #Cancer research #CAR T-cell therapy #Lymphoma #Miltenyi Biotec

CAR-T therapy could treat large B-cell lymphoma 

Biotechnology company Miltenyi Biotec has announced encouraging results from its CAR-T therapy for patients with second-line, relapsed or refractory large B-cell lymphoma.  Primary analysis of candidate zamtocabtagene autoleucel (zamto-cel) showed the therapy demonstrated significant and clinically meaningful superiority over chemoimmunotherapy. The candidate was evaluated in the DALY 2-EU trial, conducted… Read More

#Cancer Research #News

CAR-T for large B-cell lymphoma
#Advanced Therapies #Bristol Myers Squibb #FDA #Haematology #Lymphoma #Oncology

FDA approves first CAR-T therapy for marginal zone lymphoma

The US Food and Drug Administration (FDA) has approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first chimeric antigen receptor (CAR)-T therapy in the US for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of… Read More

#News #Regulatory

#Cancer research #Citius Pharmaceuticals #Immunotherapy #Lymphoma

Citius Oncology launches immunotherapy treatment in US 

Citius Oncology has announced the US commercial launch of Lymphir, its novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL).  The launch follows approval by the US Food and Drug Administration (FDA) in August 2024 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).  The FDA approval was… Read More

#News #Regulatory

Diffuse large B-cell lymphoma
#Acute Myeloid Leukaemia #Biotech #CAR-T #Lymphoma

Imviva to present data on CAR-T pipeline 

Biotechnology company Imviva Biotech is set to present data on its CAR-T pipeline at the American Society of Haematology (ASH) Annual Meeting.  Imviva will reveal progress in allogeneic cell therapy candidates being developed for multiple haematological conditions, including T-cell acute lymphoblastic leukaemia, lymphoblastic lymphoma, acute myeloid leukaemia, B-cell… Read More

#Cancer Research #News

Diffuse large B-cell lymphoma
#CAR T-cell therapy #FDA #Lymphoma

FDA grants RMAT designation to T-cell lymphoma candidate 

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, a CAR-T cell therapy developed by biotechnology company March Biosciences.  The designation was granted based on data from March Bio’s ongoing multi-centre Phase II clinical trial. Preliminary findings from the safety run-in cohort… Read More

#News #Regulatory

Non-Hodgkins lymphoma
#CAR-T #Cell therapy #Lymphoma #Natural killer cells #Phase I trial

CAR-NK therapy treats incurable lymphoma in Phase I trial

In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL).  QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More

#Cancer Research #News #Trending News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Cell therapy #FDA #Galapagos #Lymphoma #Oncology

FDA RMAT designation for mantle cell lymphoma cell therapy

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).   To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has the potential to… Read More

#News #Regulatory

Diffuse large B-cell lymphoma
#Artificial intelligence (AI) #Lantern Pharma #Lymphoma #Oncology #Orphan drugs #Phase I trial

Complete response in heavily pre-treated lymphoma patient

A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284.  Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More

#Cancer Research #Editor's Choice #News

#Combination therapy #Haematology #Lymphoma #Oncology #The Institute of Cancer Research

Drug combination treats B-cell lymphoma

Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug.   For patients with follicular lymphoma, treatment can include the drug tazemetostat – but patients have varying responses, and some see their cancer… Read More

#Cancer Research #Editor's Choice #News

Map of Europe
#AstraZeneca #European Commission #Lymphoma #Oncology #Phase III trial

Calquence plus chemoimmunotherapy approved in the EU

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for previously untreated mantle cell lymphoma (MCL).  It is approved in patients who are not eligible for autologous stem cell transplant.  The approval by the European Commission was based on positive results from… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #Cell therapy #Haematology #Lymphoma #March Biosciences #Phase II trial

Phase II trial starts for CAR-T therapy in T-cell lymphoma

March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.   “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More

#Cancer Research #News

Acute lymphoblastic leukemia
#Bantam Pharmaceutical #Clinical trials #Health Canada #Lymphoma #Small molecules

Trial evaluating treatment for R/R mature B-cell lymphomas

Bantam Pharmaceutical, a company targeting selective modulation of mitochondrial dynamics in cancer, is proceeding with a Phase I clinical trial evaluating BTM-3566 in relapsed/refractory (R/R) mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical… Read More

#Cancer Research #News

FDA
#AstraZeneca #FDA #Lymphoma #Oncology

First US approval for first-line BTK inhibitor for mantle cell lymphoma

The US Food and Drug Administration (FDA) has granted approval to acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).  The regulator also granted approval to acalabrutinib as a single agent for adults with… Read More

#News #Regulatory #Trending News